sponsored byAAAS Golden Fund

EurekAlert!, a service of AAAS
Home About us
Advanced Search
31-Oct-2014 06:59
US Eastern Time

Username:

Password:

Register

Forgot Password?

Press Releases

Breaking News

Science Business

Grants, Awards, Books

Meetings

Multimedia

Science Agencies
on EurekAlert!

US Department of Energy

US National Institutes of Health

US National Science Foundation

Calendar

Submit a Calendar Item

Subscribe/Sponsor

Links & Resources

Portals

RSS Feeds

Accessibility Option On

Options

Portal Home

Glossary

Background Articles

Research Papers

Meetings

Links & Resources

Disease in the Developing World

News Releases

Key: Meeting M      Journal J      Funder F

Showing releases 151-175 out of 912.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>

Public Release: 12-Aug-2014
XIII International Congress on Parasitology
New drug candidate for Chagas disease tested in patients in Bolivia
The Drugs for Neglected Diseases initiative announced today at the International Congress of Parasitology, the launch of a Phase II drug trial to test fexinidazole, a drug shelved in the 1980s and 'rediscovered' by DNDi nearly a decade ago, for Chagas disease patients. The drug is also being tested in patients in Africa for two other parasitic diseases, sleeping sickness and visceral leishmaniasis.
Drugs for Neglected Diseases initiative

Contact: Betina Moura
bmoura@dndi.org
55-219-812-22798
Drugs for Neglected Diseases Initiative

Public Release: 12-Aug-2014
PLOS Medicine
Heart failure is a substantial health burden in low- and middle-income countries
Heart failure is a major public health burden in many low- and middle-income countries, with substantial variation in the presentation, causes, management, and outcomes of heart failure across different LMICs, according to a study published in this week's PLOS Medicine. The study, led by Kazem Rahimi and colleagues from the George Institute for Global Health, also finds that a large proportion of patients are not receiving pharmacological treatments for heart failure.
National Institute for Health Research, Oxford Biomedical Research Centre Programme, National Institute for Health Research Career Development Fellowship

Contact: Maya Sandler
medicinepress@plos.org
PLOS

Public Release: 11-Aug-2014
GW researcher receives grant to develop genetic tools to study parasitic infections
John Hawdon, Ph.D., associate professor of microbiology, immunology, and tropical medicine at the George Washington University, was recently awarded $430,722 from the National Institutes of Health to develop a model system to study parasitic nematode infection, which will lead to greater understanding of the infective process and the host's immune response to infection.
National Institutes of Health

Contact: Lisa Anderson
lisama2@gwu.edu
202-994-3121
George Washington University

Public Release: 11-Aug-2014
Grand Challenges Canada funds seven new global health innovations in ASEAN countries
Grand Challenges Canada, funded by the Government of Canada, has announced funding of seven projects implemented in Association of Southeast Asian Nations member countries. This funding, totaling $784,000, will support projects that combine scientific, technical, social and business innovation to solve pressing global health challenges.
Grand Challenges Canada

Contact: Lode Roels
lode.roels@grandchallenges.ca
647-328-2021
Terry Collins Assoc

Public Release: 10-Aug-2014
FASEB Journal
'Worm pill' could ease autoimmune disease symptoms
Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus.

Contact: Lucy Handford
media@monash.edu
Monash University

Public Release: 8-Aug-2014
UTMB receives over $6 million to develop treatment for deadly Ebola and Marburg viruses
A University of Texas Medical Branch at Galveston researcher virologist Alex Bukreyev, professor of pathology, has been awarded two National Institutes of Health grants and a Department of Defense grant totaling more than $6 million to develop experimental drugs against both Ebola and Marburg. Each funded study involves collaborations among teams with different areas of expertise led by Christopher Basler, professor of microbiology at the Icahn School of Medicine at Mount Sinai.
National Institutes of Health, US Department of Defense

Contact: Donna Ramirez
donna.ramirez@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston

Public Release: 8-Aug-2014
Diabetes, Obesity and Metabolism
Study shows type 2 diabetics can live longer than people without the disease
Patients treated with a drug widely prescribed for type 2 diabetes can live longer than people without the condition, a large-scale study involving over 180,000 people has shown.
Bristol Myers-Squibb

Contact: Professor Craig Currie
currie@cardiff.ac.uk
07-824-807-836
Cardiff University

Public Release: 5-Aug-2014
PLOS Medicine
A campaign involving Muslim clerics has increased uptake of polio vaccination in Nigeria
A coalition campaign involving imams, Islamic school teachers, traditional rulers, doctors, journalists, and polio survivors is gradually turning the tide against polio vaccine rejection in northern Nigeria, according to experts from Nigeria writing in this week's PLOS Medicine.
National Primary Health Care Development Agency, World Health Organization

Contact: Maya Sandler
medicinepress@plos.org
PLOS

Public Release: 5-Aug-2014
PLOS Medicine
Pregnant women are often given inappropriate treatment for malaria
Not all pregnant women with symptoms of malaria seek care from their formal healthcare system and if they do seek care, they may be given inappropriate treatment because healthcare providers often fail to adhere to the standard (World Health Organization) diagnostic and treatment guidelines, according to a study by UK researchers published in this week's PLOS Medicine.
Bill and Melinda Gates Foundation

Contact: Maya Sandler
medicinepress@plos.org
PLOS

Public Release: 5-Aug-2014
PLOS Medicine
Monthly preventative treatment with a new drug combination reduces malaria in children
Preventative treatment with a monthly dose of a newer antimalarial drug can reduce the risk of malarial infection among young children, according to a study published in this week's PLOS Medicine. The study, conducted by Victor Bigira and colleagues at San Francisco General Hospital and the Makerere University College of Health Sciences in Kampala, Uganda, finds that treating young children with dihydroartemisinin-piperaquine decreased their risk of contracting malaria.
National Institutes of Health

Contact: Maya Sandler
medicinepress@plos.org
PLOS

Public Release: 4-Aug-2014
Researchers want to know how newest IBS drug helps stomach pain
The newest drug for irritable bowel syndrome has the welcome benefit of relieving the excruciating stomach pain affecting about a third of patients, and researchers want to know how.
Forest Laboratories Inc., Ironwood Pharmaceuticals

Contact: Toni Baker
tbaker@gru.edu
706-721-4421
Medical College of Georgia at Georgia Regents University

Public Release: 4-Aug-2014
Journal of the American College of Cardiology
A polypill strategy to improve global secondary cardiovascular prevention
The polypill, a combination pill taken just once a day that includes key medications for secondary prevention of heart disease, may be an effective low-cost strategy to improve adherence to medication recommendations and reduce costs.

Contact: Rachel Cagan
rcagan@acc.org
202-375-6395
American College of Cardiology

Public Release: 4-Aug-2014
Journal of Cell Biology
Key adjustment enables parasite shape-shifting
Crafty parasites undergo dramatic shape changes that enable them to adapt to different living conditions and thrive. Researchers show that these transformations might not be as difficult as they appear.

Contact: Rita Sullivan King
news@rupress.org
212-327-8603
Rockefeller University Press

Public Release: 31-Jul-2014
Elizabeth Glaser Pediatric AIDS Foundation partners with Riders for Health in Malawi
Today the Elizabeth Glaser Pediatric AIDS Foundation and Riders for Health announced a new partnership that will expedite the delivery of laboratory samples and HIV-related test results to health facilities in two districts of the Northern and Central Zones of Malawi.

Contact: Johanna Harvey
jharvey@pedaids.org
202-280-1657
Elizabeth Glaser Pediatric AIDS Foundation

Public Release: 30-Jul-2014
Academic Medicine
Journal supplement details progress in African medical education
In the first substantial publication by participants of the $130 million Medical Education Partnership Initiative, more than 225 authors detailed progress made at African institutions in a 116-page supplement being published today by the journal Academic Medicine. The collection of 32 articles includes case studies of national strategies to increase numbers of doctors and health professionals trained; educational innovations such as e-learning; research capacity development; and partnerships that leverage advances across the MEPI network.
The President's Emergency Plan for AIDS Relief, National Institutes of Health

Contact: Jeff Gray
jeffrey.gray@nih.gov
301-496-2075
NIH/Fogarty International Center

Public Release: 30-Jul-2014
Antimicrobial Agents and Chemotherapy
Dissolvable fabric loaded with medicine might offer faster protection against HIV
University of Washington bioengineers have discovered a potentially faster way to deliver a topical drug that protects women from contracting HIV. Their method spins the drug into silk-like fibers that quickly dissolve when in contact with moisture, releasing higher doses of the drug than possible with other topical materials.
National Institutes of Health

Contact: Michelle Ma
mcma@uw.edu
206-543-2580
University of Washington

Public Release: 30-Jul-2014
Science Translational Medicine
New malaria vaccine candidates identified
New vaccine targets that could help in the battle against malaria have been discovered thanks to a new technique. Researchers tested a large library of proteins from the Plasmodium falciparum parasite with antibodies produced by the immune systems of a group of infected children to see which proteins would react. Using this large-scale approach, scientists found vaccine targets that have not been recognized before and identified combinations of antigens that could provide protection against malaria when used as a vaccine.
Wellcome Trust, Medical Research Council

Contact: Mary Clarke
press.office@sanger.ac.uk
01-223-492-368
Wellcome Trust Sanger Institute

Public Release: 30-Jul-2014
New England Journal of Medicine
Drug-resistant malaria has spread to critical border regions of Southeast Asia
Drug-resistant malaria parasites have spread to critical border regions of Southeast Asia, seriously threatening global malaria control and elimination programs, according to a study published in the New England Journal of Medicine.
UK Department for International Development, Worldwide Antimalarial Resistance Network, NIH/National Institute of Allergy and Infectious Diseases Intramural Research Program, Bill & Melinda Gates Foundation

Contact: Clare Ryan
c.ryan@wellcome.ac.uk
44-020-761-17262
Wellcome Trust

Public Release: 30-Jul-2014
Trends in Microbiology
Scientists call for new strategy in pursuit of HIV-free generation
In light of the recent news that HIV has been detected in the Mississippi baby previously thought to have been cured of the disease, researchers are assessing how to help those born to HIV-infected mothers. These infants around the world are in need of new immune-based protective strategies, including vaccines delivered to mothers and babies and the means to boost potentially protective maternal antibodies, say researchers writing in Trends in Microbiology on July 30.

Contact: Mary Beth O'Leary
moleary@cell.com
617-397-2802
Cell Press

Public Release: 29-Jul-2014
New partnership to improve access to essential pain medications for people living with HIV
Today the Elizabeth Glaser Pediatric AIDS Foundation and the American Cancer Society announced a new partnership to improve access to essential pain medications for people living with HIV in Swaziland. As part of ACS' Treat the Pain initiative, this new partnership will help improve efforts to better integrate pain management into HIV/AIDS services throughout the country.

Contact: Johanna Harvey
jharvey@pedaids.org
202-280-1657
Elizabeth Glaser Pediatric AIDS Foundation

Public Release: 29-Jul-2014
PLOS Medicine
Urbanization of rural Africa associated with increased risk of heart disease and diabetes
The increasing urbanization of rural areas in sub-Saharan Africa could lead to an explosion in incidences of heart disease and diabetes, according to a new study carried out in Uganda which found that even small changes towards more urban lifestyles was associated with increased risk of cardiovascular and metabolic diseases.
African Partnership for Chronic Disease Research

Contact: Craig Brierley
craig.brierley@admin.cam.ac.uk
44-012-237-66205
University of Cambridge

Public Release: 29-Jul-2014
PLOS Medicine
Small increases in Ugandan urbanicity tied to CVD risk factors
Urban dwellers tend to have higher risk for cardiovascular diseases than people living in more rural locations. In a new study published in PLOS Medicine, Johanna Riha and colleagues have found that even within rural communities in Uganda that all lacked paved roads and running water, people living in villages with relatively more urban features were more likely to have risk factors for cardiovascular diseases such as physical inactivity, and high body mass index, even after controlling for socioeconomic status.
UK Medical Research Council

Contact: Maya Sandler
medicinepress@plos.org
PLOS

Public Release: 29-Jul-2014
PLOS Medicine
Malaria vaccine shows continued protection during 18 months of follow-up
A vaccine previously shown to reduce malaria in young infants and children reduces larger numbers of malaria cases in areas of higher malaria transmission, according to results from an ongoing clinical trial published in PLOS Medicine. The effect of vaccination diminished over time, but protection against clinical malaria remained evident 18 months after vaccination.
GSK Biologicals SA, PATH Malaria Vaccine Initiative

Contact: Maya Sandler
medicinepress@plos.org
PLOS

Public Release: 28-Jul-2014
Hepatology
Hepatitis C virus genotype 1 is most prevalent worldwide
In one of the largest prevalence studies to date, researchers from the UK provide national, regional, and global genotype prevalence estimates for the hepatitis C virus. Findings published in Hepatology, a journal of the American Association for the Study of Liver Diseases, indicate that genotype 1 is the most prevalent worldwide, with over 83 million patients infected of which one-third reside in East Asia.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 28-Jul-2014
American Journal of Tropical Medicine and Hygiene
First controlled malaria infection trial in Africa paves way for drug and vaccine development
An international research team today reports the first-ever clinical trial demonstrating controlled malaria infection in an African nation in the modern era. The study, published online in the American Journal of Tropical Medicine and Hygiene represents a significant milestone in the search for new malaria drugs and vaccines.

Contact: Preeti Singh
psingh@burnesscommunications.com
301-280-5722
Burness Communications

Showing releases 151-175 out of 912.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>